An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

Table 3 Secondary endpoint: 28-day survival rate

AT antithrombin, CI confidence interval, pAT plasma-derived antithrombin
^aThe protocol was amended to include all patients with AT activity ≤ 70% so that the patient population would more accurately reflect the intended clinical use. The (adjusted) survival rate and its 95% CI were calculated for each treatment group after stratification using the Woolson–Bean method, stratified by the AT activity (< 50%, 50–70%) at study enrollment

ISSN: 2052-0492